# EDGAR Filing Document

**Accession Number:** 0001938109
**File Stem:** 0001493152-26-000376
**Filing Date:** 2026-1
**Character Count:** 16938
**Document Hash:** 16cfc2d2a451d4487cf2d7e29eb44d4e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-000376.hdr.sgml**: 20260105

**ACCESSION NUMBER**: 0001493152-26-000376

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260105

**DATE AS OF CHANGE**: 20260105

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Pineapple Financial Inc.
- **CENTRAL INDEX KEY:** 0001938109
- **STANDARD INDUSTRIAL CLASSIFICATION:** FINANCE SERVICES [6199]
- **ORGANIZATION NAME:** 02 Finance
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-95085
- **FILM NUMBER:** 26505941

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 111 GORDON BAKER ROAD, SUITE 200
- **CITY:** NORTH YORK
- **PROVINCE COUNTRY:** A1
- **ZIP:** M2H3R1
- **BUSINESS PHONE:** 416-371-0835

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 111 GORDON BAKER ROAD, SUITE 200
- **CITY:** NORTH YORK
- **PROVINCE COUNTRY:** A1
- **ZIP:** M2H3R1
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Injective Foundation
- **CENTRAL INDEX KEY:** 0002094853

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 3119, 9 FORUM LANE
- **STREET 2:** CAMANA BAY, GEORGE TOWN
- **CITY:** GRAND CAYMAN
- **PROVINCE COUNTRY:** E9
- **ZIP:** KY1-9006
- **BUSINESS PHONE:** 345 749 9601

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 3119, 9 FORUM LANE
- **STREET 2:** CAMANA BAY, GEORGE TOWN
- **CITY:** GRAND CAYMAN
- **PROVINCE COUNTRY:** E9
- **ZIP:** KY1-9006

## Exhibit 99.11

**Exhibit 99.11**

JOINT FILING AGREEMENT

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of common stock of Pineapple Financial Inc. Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate. In accordance with Rule 13d-1(k)(1), the undersigned hereby agree to the joint filing with each other on behalf of each of them of such a statement on Schedule 13D and any amendments thereto with respect to the equity securities (as defined in Rule 13d-1(i)) of the issuer, beneficially owned by each of them. This Joint Filing Agreement shall be included as an exhibit to such Schedule 13D and any amendments thereto.

This agreement may be executed in any number of counterparts, each of which shall be deemed an original.

Dated: January 2, 2026

---

| | |
|:---|:---|
| **Injective Foundation** | **Injective Foundation** |
| By: | /s/ Glenn Kennedy |
| Name: | Glenn Kennedy |
| Title: | Director |
| /s/ Glenn Kennedy | /s/ Glenn Kennedy |
| Name: | Glenn Kennedy |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**Pineapple Financial Inc.**

*(Name of Issuer)*

**Common Shares, no par value**

*(Title of Class of Securities)*

**72303K405**

*(CUSIP Number)*

**Glenn Kennedy**<br>Injective Foundation, P.O. Box 144,3119<br>9 Forum Lane, Camana Bay George Town,<br>Grand Cayman E9 KY-1-9006<br>1-345-749 9601

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**12/30/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **72303K405** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Injective Foundation** | Name of reporting person<br>**Injective Foundation** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CAYMAN ISLANDS** | Citizenship or place of organization<br>**CAYMAN ISLANDS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**9615385.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**9615385.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**9615385.00** | Aggregate amount beneficially owned by each reporting person<br>**9615385.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**36.99%** | Percent of class represented by amount in Row (11)<br>**36.99%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** The percentages of Common Shares reported as beneficially owned are calculated based on an aggregate of 25,988,641 Common Shares issued and outstanding, including the 1,345,941 Common Shares issued and outstanding as of December 12, 2025, as set forth in the Issuer's Registration Statement on Form S-1 filed with the Securities and Exchange Commission (the "SEC") on December 12, 2025, plus the 24,642,700 Common Shares issued in the automatic exchange of Subscription Receipts as described therein and herein.

| **CUSIP No.** | **72303K405** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Glenn Kennedy** | Name of reporting person<br>**Glenn Kennedy** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CAYMAN ISLANDS** | Citizenship or place of organization<br>**CAYMAN ISLANDS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**9615385.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**9615385.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**9615385.00** | Aggregate amount beneficially owned by each reporting person<br>**9615385.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**36.99%** | Percent of class represented by amount in Row (11)<br>**36.99%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** The percentages of Common Shares reported as beneficially owned are calculated based on an aggregate of 25,988,641 Common Shares issued and outstanding, including the 1,345,941 Common Shares issued and outstanding as of December 12, 2025, as set forth in the Issuer's Registration Statement on Form S-1 filed with the SEC on December 12, 2025, plus the 24,642,700 Common Shares issued in the automatic exchange of Subscription Receipts as described therein.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Shares, no par value

**(b) Name of Issuer:**
Pineapple Financial Inc.

**(c) Address of Issuer's Principal Executive Offices:**
1 Unit 200, 11 Gordon Baker Road, North York, A6, M2H3R1

**Item 4. Purpose of Transaction**

The information set forth in Item 3 and Item 6 hereof is hereby incorporated herein by reference.

The Foundation holds the securities of the Issuer directly, and acquired those securities as an investment in the Issuer in connection with the Issuer's launch of its INJ digital asset treasury strategy (the "DAT"). The Reporting Persons may engage in discussions with management, the Issuer's board of directors, other shareholders of the Issuer and other relevant parties concerning the business, operations, board composition, management, strategy and future plans of the Issuer, particularly as they relate to the DAT strategy. Pursuant to the Securities Purchase Agreement, the Issuer has agreed to take all actions necessary to cause one additional director to be appointed to its board of directors (the "Board"), after consultation with the Foundation. The Foundation nominated, and effective as of December 18, 2025, the Board appointed, Anthony Georgiades to the Board. The Reporting Persons intend to re-examine their investment from time to time and, depending on prevailing market conditions, other investment opportunities, liquidity requirements or other investment considerations the Reporting Persons deem material, the Reporting Persons may from time to time acquire additional securities of the Issuer in the open market, block trades, negotiated transactions, or otherwise and may also dispose of all or a portion of the Issuer's securities, in open market or privately negotiated transactions, and/or enter into derivative transactions with institutional counterparties with respect to the Issuer's securities, in each case, subject to limitations under applicable law.

The Reporting Persons have not yet determined which, if any, of the above courses of action they may ultimately take. The Reporting Persons' future actions with regard to the Issuer are dependent on their evaluation of the factors listed above, circumstances affecting the Issuer in the future, including prospects of the Issuer, general market and economic conditions and other factors deemed relevant. The Reporting Persons reserve the right to determine in the future whether to change the purpose or purposes described above or whether to adopt plans or proposals of the type specified above or otherwise.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The responses of each of the Reporting Persons with respect to Rows 11, 12, and 13 of the cover pages of this Schedule 13D that relate to the aggregate number and percentage of Common Shares (including but not limited to footnotes to such information) are incorporated herein by reference.

**(b)**
The responses of each of the Reporting Persons with respect to Rows 7, 8, 9, and 10 of the cover pages of this Schedule 13D that relate to the number of Common Shares as to which each of the Reporting Persons has sole or shared power to vote or to direct the vote of and sole or shared power to dispose of or to direct the disposition of (including but not limited to footnotes to such information) are incorporated herein by reference.

The 9,615,385 Common Shares are held directly by the Foundation and may be deemed to be beneficially owned by Mr. Kennedy because Mr. Kennedy has investment and dispositive control over such Common Shares. Mr. Kennedy disclaims beneficial ownership of these securities.

**(c)**
The information set forth in Item 3 hereof is incorporated herein by reference.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

The information set form in Item 3 hereof is incorporated herein by reference.

Registration Rights

On September 2, 2025, the parties to the Securities Purchase Agreement entered into a registration rights agreement (the "Registration Rights Agreement") pursuant to which the Issuer agreed to file a registration statement with the Commission, within five (5) business days of receiving Shareholder Approval, registering the resale of the Common Shares issuable upon the exchange of the Subscription Receipts. Pursuant to the terms of the Registration Rights Agreement, the Company must keep the Registration Statement continuously effective for resale under Rule 415 until the earlier of (i) the date on which all registrable securities are sold and (ii) the date on which the registrable securities may be resold without registration, without regard to any volume or manner-of-sale limitations and without current public information under Rule 144. On November 7, 2025 and December 5, 2025, the parties to the Securities Purchase Agreement entered into the First Amendment to Registration Rights Agreement and Second Amendment to Registration Rights Agreement, respectively, each of which extended the date by which the Issuer was obligated to file the Registration Statement pursuant to the Registration Rights Agreement.

The foregoing description of the Registration Rights Agreement and the amendments thereto does not purport to be complete and is qualified in its entirety by reference to the Registration Rights Agreement, the First Amendment to Registration Rights Agreement and the Second Amendment to Registration Rights Agreement, the forms of which are filed as Exhibits 99.7, 99.8, and 99.9, respectively, and incorporated herein by reference.

Lock-Up

Pursuant to the Securities Purchase Agreement, the Issuer and certain purchasers party to the Securities Purchase Agreement, including the Foundation, entered into a Lock-up Agreement, dated as of September 4, 2025 (the "Lock-up Agreement"). Under the Lock-up Agreement, the Foundation has agreed not to offer, sell, pledge or otherwise dispose of any Common Shares or securities convertible, exercisable or exchangeable into Common Shares, of the Issuer for a period of twelve (12) months following the Effective Date (as defined in the Securities Purchase Agreement), provided that, if at any time following the Effective Date, the closing sale price of the Common Shares equals or exceeds (i) $7.588, (ii) $11.382, (iii) $15.176, or (iv) $18.970, then in each case 25% of the securities held by the Foundation shall be immediately and irrevocably released from the restrictions set forth in the Lock-up Agreement. The Lock-up Agreement includes customary exceptions permitting certain transfers, including, without limitation, transfers to affiliates, to family members or for estate-planning purposes or pursuant to a bona fide third-party tender offer, merger or similar transaction, in each case conditioned on the transferee agreeing to be bound by the lock-up.

The foregoing description of the Lock-Up Agreement does not purport to be complete and is qualified in its entirety by reference to the Lock-Up Agreement, the form of which is filed as Exhibit 99.10 and incorporated herein by reference.

A Joint Filing Agreement, dated as of January 2, 2026, by and among the Reporting Persons has been executed by the Reporting Persons, a copy of which is attached hereto as Exhibit 99.11 and is incorporated herein by reference.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Injective Foundation

**Signature:** /s/ Glenn Kennedy

**Name/Title:** Glenn Kennedy, Director

**Date:** 01/02/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Glenn Kennedy

**Signature:** /s/ Glenn Kennedy

**Name/Title:** Glenn Kennedy

**Date:** 01/02/2026